Start-Up Eidos Surfs Crest Of TTR Amyloidosis Wave
Executive Summary
Emerging Company Profile: The Phase III success of Pfizer's tafamidis means Eidos’ protein misfolding drug AG10 is not the first – but it is validated and differentiated, says BridgeBio-backed start-up Eidos.
You may also be interested in...
Deal Watch: Roche Partners With Dyno On AAV-Delivered Gene Therapies
Also, deals between Boehringer Ingelheim/Oxford BioTherapeutics, Bausch/Eyenovia, Ligand/HitGen, Moderna/Merck & Co., Vincera/Bayer, Genentech/Kineta, Selecta/IGAN, RedHill/AstraZeneca, Urovant/Sunovion, Biogen/Scribe, BridgeBio/Eidos, Elevar/Taiba
BridgeBio Pharma’s Pipeline Expansion Continues As Existing Portfolio’s Milestones Approach
The company already has more than 20 subsidiaries developing treatments for monogenic diseases and genetically defined cancers, but its deal-making pace has not slowed.
Deal Watch: Castle Creek Likes Partner Fibrocell Enough To Buy It
Dermatology-focused regenerative medicine firm Fibrocell has been reviewing strategic opportunities for more than a year; April’s FCX-007 license deal with Castle Creek results in buyout.
Need a specific report? 1000+ reports available
Buy Reports